Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1975-1978, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohta, M.
Right arrow Articles by Ohta, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohta, M.
Right arrow Articles by Ohta, K.

Clinical Chemistry, Vol 42, 1975-1978, Copyright © 1996 by American Association for Clinical Chemistry

Radioimmunoprecipitation assay for glutamic acid decarboxylase antibodies evaluated clinically with sera from patients with insulin- dependent diabetes mellitus

M Ohta, H Obayashi, K Takahashi, Y Kitagawa, K Nakano, S Matsuo, M Nishimura, N Itoh and K Ohta
Clinical Research Center, Utano National Hospital, Kyoto, Japan.

We evaluated a new, commercially developed radioimmunoprecipitation assay for measuring glutamic acid decarboxylase (GAD) antibodies by using recombinant human GAD65. The intra- and interassay CVs were 8.0% (n = 20) and 8.6% (n = 15), respectively. We found GAD antibodies in 74% (23 of 31; 95% confidence interval 55-88%), 70% (14 of 20; 46-88%), and 65% (28 of 43; 49-79%) of patients at, respectively, < or = 1 year, 1-2 years, and 2-4 years after the onset of insulin-dependent diabetes mellitus (IDDM) and in 30% (30 of 99; 21-40%) of patients with long- term diabetes (4-22 years). We also detected GAD antibodies in 8% (9 of 106; 4-16%) of patients with non-insulin-dependent diabetes mellitus (NIDDM). The frequency of GAD antibodies in the NIDDM group was markedly higher in the insulin-deficient patients [67% (6 of 9; 30- 93%)], who initially were nonketotic and non-insulin-dependent for > or = 6 months but later became insulin dependent, than in the non-insulin- deficient patients [3% (3 of 97; 1-9%)]. This new commercial assay is easy to use and provides a specific and sensitive method for evaluating GAD antibodies in IDDM.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Ankelo, A. Westerlund-Karlsson, J. Ilonen, M. Knip, K. Savola, P. Kankaanpaa, L. Merio, H. Siitari, and A. Hinkkanen
Time-resolved Fluorometric Assay for Detection of Autoantibodies to Glutamic Acid Decarboxylase (GAD65)
Clin. Chem., June 1, 2003; 49(6): 908 - 915.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Obayashi, G. Hasegawa, M. Fukui, K. Kamiuchi, A. Kitamura, M. Ogata, T. Kanaitsuka, H. Shigeta, Y. Kitagawa, K. Nakano, et al.
Tumor Necrosis Factor Microsatellite Polymorphism Influences the Development of Insulin Dependency in Adult-Onset Diabetes Patients with the DRB1*1502-DQB1*0601 Allele and Anti-Glutamic Acid Decarboxylase Antibodies
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3348 - 3351.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
M. Kimura, K.-I. Tatsumi, H. Tada, M. Ikemoto, Y. Fukuda, A. Kaneko, M. Kato, Y. Hidaka, and N. Amino
Enzyme Immunoassay for Autoantibodies to Human Liver-Type Arginase and Its Clinical Application
Clin. Chem., January 1, 2000; 46(1): 112 - 117.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.